Shareholders of Norwegian contrast developer Hafslund Nycomedhave approved a plan to demerge the company's energy businessfrom its pharmaceutical unit. Under the plan, the Oslo company'spharmaceutical business will be known as Nycomed ASA, while
Shareholders of Norwegian contrast developer Hafslund Nycomedhave approved a plan to demerge the company's energy businessfrom its pharmaceutical unit. Under the plan, the Oslo company'spharmaceutical business will be known as Nycomed ASA, while theenergy unit will be called Hafslund ASA. Nycomed shares will betraded on the Oslo, London, and Copenhagen exchanges, while NycomedAmerican Depository Receipts will be listed on the New York StockExchange under the symbol "NYD."
Study Shows No Impact of Hormone Therapy on PET/CT with 18F-Piflufolastat in PCa Imaging
May 7th 2025For patients with recurrent or metastatic prostate cancer, new research findings showed no significant difference in the sensitivity of 18F-piflufolastat PET/CT between patients on concurrent hormone therapy and those without hormone therapy.
Study Shows No Impact of Hormone Therapy on PET/CT with 18F-Piflufolastat in PCa Imaging
May 7th 2025For patients with recurrent or metastatic prostate cancer, new research findings showed no significant difference in the sensitivity of 18F-piflufolastat PET/CT between patients on concurrent hormone therapy and those without hormone therapy.
2 Commerce Drive
Cranbury, NJ 08512